Abstract
Brazil is increasingly better positioned to compete in the field of advanced therapies. In particular, five gene therapy products were registered by ANVISA, paving the way for new proposals of clinical evaluation. Our group has been investing in the development of an intervention for melanoma that uses improved adenoviral vectors to deliver two genes, p14ARF and interferon-², which cooper…